# Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

> **NCT02106585** · PHASE1 · COMPLETED · sponsor: **Akros Pharma Inc.** · enrollment: 94 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** JTT-251 or Placebo

## Key facts

- **NCT ID:** NCT02106585
- **Lead sponsor:** Akros Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2014-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02106585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02106585, "Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02106585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*